- Home
- ANL vs PMVP Comparison
ANL vs PMVP Comparison
Compare ANL & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- PMVP
- Stock Information
- Founded
- ANL 2004
- PMVP 2013
- Country
- ANL Cayman Islands
- PMVP United States
- Employees
- ANL N/A
- PMVP N/A
- Industry
- ANL
- PMVP Medicinal Chemicals and Botanical Products
- Sector
- ANL
- PMVP Health Care
- Exchange
- ANL Nasdaq
- PMVP Nasdaq
- Market Cap
- ANL 79.0M
- PMVP 85.5M
- IPO Year
- ANL 2023
- PMVP 2020
- Fundamental
- Price
- ANL $2.05
- PMVP $1.37
- Analyst Decision
- ANL Strong Buy
- PMVP Strong Buy
- Analyst Count
- ANL 2
- PMVP 3
- Target Price
- ANL $9.00
- PMVP $5.33
- AVG Volume (30 Days)
- ANL 13.8K
- PMVP 175.1K
- Earning Date
- ANL 02-24-2025
- PMVP 02-27-2025
- Dividend Yield
- ANL N/A
- PMVP N/A
- EPS Growth
- ANL N/A
- PMVP N/A
- EPS
- ANL N/A
- PMVP N/A
- Revenue
- ANL $5,000,000.00
- PMVP N/A
- Revenue This Year
- ANL N/A
- PMVP N/A
- Revenue Next Year
- ANL N/A
- PMVP N/A
- P/E Ratio
- ANL N/A
- PMVP N/A
- Revenue Growth
- ANL N/A
- PMVP N/A
- 52 Week Low
- ANL $1.85
- PMVP $1.32
- 52 Week High
- ANL $17.48
- PMVP $2.26
- Technical
- Relative Strength Index (RSI)
- ANL 44.92
- PMVP 33.56
- Support Level
- ANL $2.00
- PMVP $1.32
- Resistance Level
- ANL $2.19
- PMVP $1.50
- Average True Range (ATR)
- ANL 0.27
- PMVP 0.07
- MACD
- ANL -0.01
- PMVP -0.01
- Stochastic Oscillator
- ANL 16.81
- PMVP 16.61
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.